⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Histidinal SCHEMBL21577095 | 1.00 | — | — | |
| L-Histidinal SCHEMBL234364 | 1.00 | — | — | |
| L-Histidinal SCHEMBL829479 | 0.98 | — | — | |
| L-Histidinal SCHEMBL829480 | 0.98 | — | — | |
| SCHEMBL2004337 | 0.78 | TP53 (0.36) | — | |
| SCHEMBL4292875 | 0.78 | AKR1B1 (0.32) | — | |
| SCHEMBL3167029 | 0.78 | AKR1B1 (0.32) | — | |
| SCHEMBL15072037 | 0.77 | — | — | |
| L-Histidinal SCHEMBL31210116 | 0.77 | BLM (0.41) | — | |
| SCHEMBL30414674 | 0.76 | CYP3A4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646404-A1 | PEPTIDE-HISTIDINAL CONJUGATES AS AN ANTI-MALARIAL AGENTS | Council of Scientific & Industrial Research (IN) | 2025-11-12 | — | — | EP | claimed |
| CN-119220474-B | Escherichia coli genetically engineered bacterium for producing L-histidine through fermentation, method and application | 天津科技大学 | 2025-02-25 | — | — | CN | claimed |
| CN-119220474-A | Escherichia coli genetically engineered bacterium for producing L-histidine through fermentation, method and application | 天津科技大学 | 2024-12-31 | — | — | CN | claimed |
| CN-118688333-A | Marker related to allergic rhinitis and kit thereof | 厦门市迈理奥科技有限公司 | 2024-09-24 | — | — | CN | claimed |
| WO-2024147153-A1 | PEPTIDE-HISTIDINAL CONJUGATES AS AN ANTI-MALARIAL AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-07-11 | — | — | WO | claimed |
| EP-4376826-A1 | AMINO ACID COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF POST-ACUTE SEQUELAE OF COVID-19 | Axcella (Assignment for the benefit of Creditors), LLC (US) | 2024-06-05 | — | — | EP | claimed |
| CN-117554455-A | Establishment of interaction fingerprint of triazole derivative and mango bacillus anthracis protein and detection method of differential protein | 海南师范大学 | 2024-02-13 | — | — | CN | claimed |
| US-11833127-B2 | Compositions and methods for the treatment of fat infiltration in muscle | AXCELLA HEALTH INC. (US) | 2023-12-05 | — | — | US | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-11571404-B2 | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting | AXCELLA HEALTH INC. (US) | 2023-02-07 | — | — | US | claimed |
| US-10973793-B2 | Compositions and methods for the treatment of fat infiltration in muscle | AXCELLA HEALTH INC. (US) | 2021-04-13 | — | — | US | claimed |
| US-10828335-B2 | Production of midbrain dopaminergic neurons and methods for the use thereof | FUJIFILM Cellular Dynamics, Inc. (US) | 2020-11-10 | — | — | US | claimed |
| US-20200306214-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES AND DISORDERS ASSOCIATED WITH ONE OR BOTH OF HYPERAMMONEMIA OR MUSCLE WASTING | AXCELLA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC | 2020-10-01 | — | — | US | claimed |
| US-20200281882-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FAT INFILTRATION IN MUSCLE | AXCELLA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC | 2020-09-10 | — | — | US | claimed |
| US-10682325-B2 | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting | AXCELLA HEALTH INC. (US) | 2020-06-16 | — | — | US | claimed |
| EP-3554493-A1 | AMINO ACID COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE DISEASES AND DISORDERS | Axcella Health Inc. (US) | 2019-10-23 | — | — | EP | claimed |
| CN-110267655-A | The treatment method of amino acid composition and muscle disease and illness | 胺细拉健康公司 | 2019-09-20 | — | — | CN | claimed |
| WO-2018118957-A1 | AMINO ACID COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE DISEASES AND DISORDERS | AXCELLA HEALTH INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20060034817-A1 | Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase | UNIVERSITY OF SOUTH CAROLINA | 2006-02-16 | — | — | US | claimed |
| EP-0478502-A2 | Histidinol dehydrogenase protein, DNA and muteins and transgenic plants thereof | CIBA-GEIGY AG (CH) | 1992-04-01 | — | — | EP | claimed |